H2: Perforant Path Synapse Loss via Early Complement Cascade Activation

Mechanistic Overview

H2: Perforant Path Synapse Loss via Early Complement Cascade Activation starts from the claim that modulating C1QA, C1QB, C3, ITGAM within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview H2: Perforant Path Synapse Loss via Early Complement Cascade Activation starts from the claim that modulating C1QA, C1QB, C3, ITGAM within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview H2: Perforant Path Synapse Loss via Early Complement Cascade Activation starts from the claim that Layer II synapses onto dentate granule cells are selectively dismantled via C1q/C3–dependent complement pathways.

...

Mechanistic Overview

H2: Perforant Path Synapse Loss via Early Complement Cascade Activation starts from the claim that modulating C1QA, C1QB, C3, ITGAM within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview H2: Perforant Path Synapse Loss via Early Complement Cascade Activation starts from the claim that modulating C1QA, C1QB, C3, ITGAM within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview H2: Perforant Path Synapse Loss via Early Complement Cascade Activation starts from the claim that Layer II synapses onto dentate granule cells are selectively dismantled via C1q/C3–dependent complement pathways. Soluble tau oligomers binding to neuronal NMDA receptors trigger microglial phagocytosis through CR3. Anti-C1q antibodies are in Phase I development. However, the mechanistic chain from tau oligomers to complement activation is underspecified, and C1q deposition is observed in normal aging and non-AD tauopathies, suggesting it may be a non-specific response to neuronal stress. Framed more explicitly, the hypothesis centers C1QA, C1QB, C3, ITGAM within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `debate_synthesizer`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating C1QA, C1QB, C3, ITGAM or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.62, novelty 0.58, feasibility 0.58, impact 0.65, mechanistic plausibility 0.55, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `C1QA, C1QB, C3, ITGAM` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA, C1QB, C3, ITGAM or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. C1q and C3 accumulate at excitatory synapses in postmortem EC at Braak I-II. Identifier 28970483. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Soluble tau oligomers directly activate complement in early AD mouse models. Identifier 31196934. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Layer II neurons express unusually high levels of GluN2B-containing NMDA receptors. Identifier 29896969. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Mechanistic chain tau oligomers → NMDA → complement activation is underspecified. Identifier 31196934. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. C1q deposition observed in normal aging and non-AD tauopathies. Identifier 28970483. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Complement may be protective refinement response rather than driver of pathology. Identifier 28970483. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.61`, debate count `1`, citations `0`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA, C1QB, C3, ITGAM in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "H2: Perforant Path Synapse Loss via Early Complement Cascade Activation". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1QA, C1QB, C3, ITGAM within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers C1QA, C1QB, C3, ITGAM within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `debate_synthesizer`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating C1QA, C1QB, C3, ITGAM or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.62, novelty 0.58, feasibility 0.58, impact 0.65, mechanistic plausibility 0.55, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `C1QA, C1QB, C3, ITGAM` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA, C1QB, C3, ITGAM or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. C1q and C3 accumulate at excitatory synapses in postmortem EC at Braak I-II. Identifier 28970483. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Soluble tau oligomers directly activate complement in early AD mouse models. Identifier 31196934. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Layer II neurons express unusually high levels of GluN2B-containing NMDA receptors. Identifier 29896969. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Mechanistic chain tau oligomers → NMDA → complement activation is underspecified. Identifier 31196934. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. C1q deposition observed in normal aging and non-AD tauopathies. Identifier 28970483. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Complement may be protective refinement response rather than driver of pathology. Identifier 28970483. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.61`, debate count `1`, citations `0`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA, C1QB, C3, ITGAM in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "H2: Perforant Path Synapse Loss via Early Complement Cascade Activation". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting C1QA, C1QB, C3, ITGAM within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers C1QA, C1QB, C3, ITGAM within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `debate_synthesizer`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating C1QA, C1QB, C3, ITGAM or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.62, novelty 0.58, feasibility 0.58, impact 0.65, mechanistic plausibility 0.55, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `C1QA, C1QB, C3, ITGAM` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of C1QA, C1QB, C3, ITGAM or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

C1q and C3 accumulate at excitatory synapses in postmortem EC at Braak I-II. Identifier 28970483. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Soluble tau oligomers directly activate complement in early AD mouse models. Identifier 31196934. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Layer II neurons express unusually high levels of GluN2B-containing NMDA receptors. Identifier 29896969. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Mechanistic chain tau oligomers → NMDA → complement activation is underspecified. Identifier 31196934. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

C1q deposition observed in normal aging and non-AD tauopathies. Identifier 28970483. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Complement may be protective refinement response rather than driver of pathology. Identifier 28970483. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.61`, debate count `1`, citations `0`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates C1QA, C1QB, C3, ITGAM in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "H2: Perforant Path Synapse Loss via Early Complement Cascade Activation".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting C1QA, C1QB, C3, ITGAM within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.